Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bacterial de novo purine biosynthesis pathway is an essential metabolic route for synthesizing purine nucleotides (AMP and GMP) from small molecule precursors. It is crucial for DNA/RNA synthesis, energy transfer, and cell signaling. Differences between bacterial and eukaryotic pathways make it an attractive target for antibacterial drug development. The pathway involves multiple enzymatic steps, starting with PRPP and glutamine, ultimately leading to IMP, the precursor for AMP and GMP. Key regulatory mechanisms, particularly the PurR repressor, control pathway activity. Inhibition of this pathway can disrupt bacterial growth, virulence, and biofilm formation.
Inhibition of purine nucleotide biosynthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial De Novo Purine Biosynthesis Pathway (Purine Biosynthesis (Bacterial)).